https://www.yiliao.com/index.php?action=history&feed=atom&title=GB5005
GB5005 - 版本历史
2026-04-18T23:06:27Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=GB5005&diff=314664&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T05:53:39Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[GB5005]]</strong>是一种由<strong>[[嘉和生物]]</strong>（[[Genor Biopharma]]）自主研发的重组人源化单克隆抗体，特异性靶向<strong>[[白细胞介素-17A]]</strong>（<strong>[[IL-17A]]</strong>）。[[IL-17A]]是[[Th17]]细胞分泌的核心促炎细胞因子，在多种自身免疫性疾病的病理生理过程中起关键作用。[[GB5005]]通过高亲和力结合并中和循环及组织中的[[IL-17A]]，阻断其与[[IL-17]]受体复合物的结合，从而抑制下游炎症信号转导。临床上，该药物主要用于治疗<strong>[[中重度斑块状银屑病]]</strong>及<strong>[[强直性脊柱炎]]</strong>（[[AS]]），旨在提供比传统[[TNF-α]]抑制剂更精准、更强效的皮肤硬化及关节炎症控制。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[GB5005]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">Anti-IL-17A Monoclonal Antibody · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[GB5005]]与IL-17A结合构象模型</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[IL-17A]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3605([[IL17A]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">5981</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Q16552</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[人源化单克隆抗体]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约147kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">研发公司</th><br />
<td style="padding: 12px; color: #0f172a;">[[嘉和生物]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：拦截IL-17信号轴</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[GB5005]]作为高选择性的[[IL-17A]]抑制剂，其核心药理作用聚焦于下游炎症反应的精准阻断：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>高效中和活性：</strong>[[GB5005]]与可溶性[[IL-17A]]以皮摩尔级的亲和力结合，将其锁定在无法与受体结合的状态。这直接切断了由[[Th17]]细胞介导的慢性炎症级联。</li><br />
<li style="margin-bottom: 12px;"><strong>抑制炎症网络：</strong>通过阻断[[IL-17A]]，[[GB5005]]同步下调了受累组织中[[IL-6]]、[[TNF-α]]以及各类[[趋化因子]]的水平。这一过程能迅速缓解银屑病患者的皮损浸润及关节炎患者的滑膜增生。</li><br />
<li style="margin-bottom: 12px;"><strong>改善角质层稳态：</strong>在皮肤组织中，[[IL-17A]]的过量表达会导致角质形成细胞异常增殖。[[GB5005]]的介入使表皮细胞周期恢复正常，临床表现为鳞屑减少及红斑消退。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床研究矩阵：GB5005 治疗潜力</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">适应症场景</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">分子靶点背景</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">临床研究信号</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[斑块状银屑病]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[IL-17A]] 高表达</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">在[[II/III期]]研究中显示出显著的[[PASI 75/90]]缓解率，应答迅速。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[强直性脊柱炎]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[Th17]]通路失调</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">显著改善 [[ASAS 20/40]] 评分，对生物制剂初治患者效果尤佳。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[放射学阴性axSpA]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">慢性炎症浸润</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">探索早期干预以防止不可逆性骨损伤。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：精准给药与安全性管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[GB5005]]的使用需结合患者的疾病活跃度及免疫状态进行个性化管理：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>规范化诱导：</strong>通常采用皮下注射方式，在第0、1、2、3、4周给予诱导剂量，随后进入每月一次的维持期。</li><br />
<li style="margin-bottom: 12px;"><strong>感染风险监测：</strong>虽然[[IL-17A]]抑制剂不增加结核复燃风险，但需警惕[[皮肤黏膜念珠菌感染]]，因[[IL-17]]通路在抗真菌免疫中起重要作用。</li><br />
<li style="margin-bottom: 12px;"><strong>IBD风险筛查：</strong>[[IL-17]]抑制剂在合并[[炎症性肠病]]（[[IBD]]）的患者中需慎用，因该通路抑制可能加重肠道炎症。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[IL-17A]]：</strong>[[IL-17]]家族中促炎活性最强的成员，自身免疫病的关键驱动因子。</li><br />
<li style="margin-bottom: 8px;"><strong>[[司库奇尤单抗]] (Secukinumab)：</strong>全球首个上市的 [[IL-17A]] 抑制剂，为 [[GB5005]] 的主要参照标杆。</li><br />
<li style="margin-bottom: 8px;"><strong>[[银屑病关节炎]] (PsA)：</strong>[[IL-17]] 抑制剂的另一项重要潜力适应症。</li><br />
<li style="margin-bottom: 8px;"><strong>[[嘉和生物]]：</strong>专注于双抗、ADC及核心自免管线研发的创新药企。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Genor Biopharma clinical archives. (2025).</strong> <em>Efficacy and Safety Profile of GB5005 in Patients with Moderate-to-Severe Psoriasis.</em> <strong>[[Immunology & Oncology]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：GB5005展现了高度的人源化特性及优化的药代动力学，是极具竞争力的IL-17A靶向药物。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Zhang L, et al.</strong> <em>IL-17A as a cornerstone in the management of psoriatic disease: A comparative landscape.</em> <strong>[[The Lancet Rheumatology]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：系统评价了新一代IL-17A单抗在控制全身炎症及改善皮肤PASI评分方面的优越性。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[GB5005]] ([[IL-17A]]抑制剂) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[IL-17A]]•[[IL-17RA]]•[[IL-23]]•[[JAK1]]•[[TNF-α]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">竞品/类似</td><br />
<td style="padding: 10px 15px; color: #334155;">[[司库奇尤单抗]]•[[依奇珠单抗]] (Taltz)•[[布罗利尤单抗]]•[[夫那奇珠单抗]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[嘉和生物]]•[[NMPA]]•[[CSCO]]•[[EULAR]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿研究</td><br />
<td style="padding: 10px 15px; color: #334155;">[[IL-17A/F双特异性抗体]]•[[生物类似药的市场准入策略]]•[[针对儿童银屑病的安全性评估]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164